In a session during the final full day of conference activity at AXS24, experts from CVS Health and Surescripts emphasized ...

While the novel payment models for expensive cell and gene therapies have been effective, they need to continue evolving, ...

William R. Short, MD, MPH, of the University of Pennsylvania, discusses how a label update for bictegravir can help provide ...

Data from the study showed that exa-cel prevented vaso-occlusive crises in all but 1 of the 30 evaluable patients for at ...

The health-system specialty pharmacy has the unique ability to coordinate better with the provider and take a team approach ...

A new definition of rectal cancer in the Netherlands prompted reclassification of cancer as sigmoid tumors, which could lead ...

Approximately 65% of workers are covered by self-funded employer benefit plans, according to new data from ICON plc.

Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ...

There are multiple levers that need to be pulled to allow biosimilars to come to market more broadly in the US, explained ...

In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an ...

Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance ...

The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but ...